Patents by Inventor Charalambos Kaittanis

Charalambos Kaittanis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200222452
    Abstract: A method for treating leukemia is disclosed. The method comprises administering to a subject with leukemia an effective amount of a pharmaceutical composition comprising a naked iron oxide nanoparticle, wherein the composition is not loaded with an active agent. Also disclosed is a method for treating cancer. The method comprises administering an effective amount of a pharmaceutical composition comprising a metal oxide nanoparticle comprising a polymeric coating over a metal oxide core, wherein the nanoparticle is loaded with a reactive oxygen species (ROS)-inducing agent.
    Type: Application
    Filed: September 11, 2019
    Publication date: July 16, 2020
    Applicants: Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University
    Inventors: Jan GRIMM, Monica L. GUZMAN, Charalambos KAITTANIS
  • Publication number: 20200054744
    Abstract: The present invention provides methods of treating disease by modulation of PSMA activity. Such modulations can lead to, for example, alterations in cancer tumor metabolism, oxygenation, vascularization, and metastasis.
    Type: Application
    Filed: April 29, 2019
    Publication date: February 20, 2020
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Jan Grimm, Charalambos Kaittanis
  • Publication number: 20190388542
    Abstract: The present invention relates to the field of drug delivery, in particular the delivery of unmodified cargo molecules (such as doxorubicin and Taxol©) using iron oxide nanoparticles as therapeutic delivery agents. Specifically described are methods to entrap cargo (i.e. known therapeutics (drugs) and other types of molecules) into the exterior coating of iron oxide nanoparticles, including iron oxide nanoparticles approved for use in humans. Additionally, methods describe the use of such drug-loaded nanoparticles as therapeutic delivery agents. Further, methods include quantifying and visualizing the amount of cargo molecule loading levels when preparing these therapeutic agents and then quantifying and visualizing the amount of delivery (i.e. unloading) of these cargo molecules from these nanoparticles using compact magnetic relaxometers, common NMR instruments and magnetic resonance imaging (MRI) instruments.
    Type: Application
    Filed: December 6, 2018
    Publication date: December 26, 2019
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Charalambos KAITTANIS, Jan GRIMM
  • Publication number: 20190277841
    Abstract: Methods, systems, compositions include biocompatible polymer coated nanoceria that function as aqueous redox catalyst with enhanced activity at an acidic to moderately alkaline pH value between 1 and 8. The compositions are used as oxidizing agents for decomposition, decontamination or inactivation of organic contaminants, such as, pesticides and chemical warfare agents. Another use includes nanoceria as targetable nanocatalyst prepared by conjugating various targeting ligands to the nanoparticle coating to form a colorimetric or fluorescent probe in immunoassays and other molecule binding assays that involve the use of a molecule in solution that changes the color of the solution or emits a fluorescent signal, where localization of nanoceria to organs or tissue is assessed by treatment with an oxidation sensitive dye or other detection devices.
    Type: Application
    Filed: March 19, 2019
    Publication date: September 12, 2019
    Inventors: Jesus Manuel PEREZ, Atul ASATI, Santimukul SANTRA, Charalambos KAITTANIS, Sudip NATH
  • Publication number: 20190255101
    Abstract: Differential surface-charge-dependent localization of nanoceria in normal cells and cancer cells plays a critical role in the toxicity profile of a nanoceria particle. Engineered surface-coated cerium oxide nanoparticles with different surface charges that are positive, negative and neutral provide therapeutic results for normal and cancer cell lines. Results show that nanoceria with a positive or neutral charge enters most of the cell lines studied, while nanoceria with a negative charge internalizes mostly in the cancer cell lines. Moreover, upon entry into the cells, nanoceria is localized to different cell compartments (e.g. cytoplasm and lysosomes) depending on the nanoparticle surface charge. The internalization and subcellular localization of nanoceria plays a key role in the nanoparticle cytotoxicity profile, exhibiting significant toxicity when they localize in the lysosomes of the cancer cell lines.
    Type: Application
    Filed: February 25, 2019
    Publication date: August 22, 2019
    Inventors: Jesus Manuel Perez, Atul Asati, Santimukul Santra, Charalambos Kaittanis
  • Patent number: 10261074
    Abstract: Methods, systems, compositions include biocompatible polymer coated nanoceria that function as aqueous redox catalyst with enhanced activity at an acidic to moderately alkaline pH value between 1 and 8. The compositions are used as oxidizing agents for decomposition, decontamination or inactivation of organic contaminants, such as, pesticides and chemical warfare agents. Another use includes nanoceria as targetable nanocatalyst prepared by conjugating various targeting ligands to the nanoparticle coating to form a colorimetric or fluorescent probe in immunoassays and other molecule binding assays that involve the use of a molecule in solution that changes the color of the solution or emits a fluorescent signal, where localization of nanoceria to organs or tissue is assessed by treatment with an oxidation sensitive dye or other detection devices.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: April 16, 2019
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Jesus Manuel Perez, Atul Asati, Santimukul Santra, Charalambos Kaittanis, Sudip Nath
  • Patent number: 10213458
    Abstract: Differential surface-charge-dependent localization of nanoceria in normal cells and cancer cells plays a critical role in the toxicity profile of a nanoceria particle. Engineered surface-coated cerium oxide nanoparticles with different surface charges that are positive, negative and neutral provide therapeutic results for normal and cancer cell lines. Results show that nanoceria with a positive or neutral charge enters most of the cell lines studied, while nanoceria with a negative charge internalizes mostly in the cancer cell lines. Moreover, upon entry into the cells, nanoceria is localized to different cell compartments (e.g. cytoplasm and lysosomes) depending on the nanoparticle surface charge. The internalization and subcellular localization of nanoceria plays a key role in the nanoparticle cytotoxicity profile, exhibiting significant toxicity when they localize in the lysosomes of the cancer cell lines.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: February 26, 2019
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Jesus Manuel Perez, Atul Asati, Santimukul Santra, Charalambos Kaittanis
  • Publication number: 20180296595
    Abstract: A method for treating leukemia is disclosed. The method comprises administering to a subject with leukemia an effective amount of a pharmaceutical composition comprising a naked iron oxide nanoparticle, wherein the composition is not loaded with an active agent. Also disclosed is a method for treating cancer. The method comprises administering an effective amount of a pharmaceutical composition comprising a metal oxide nanoparticle comprising a polymeric coating over a metal oxide core, wherein the nanoparticle is loaded with a reactive oxygen species (ROS)-inducing agent.
    Type: Application
    Filed: September 9, 2016
    Publication date: October 18, 2018
    Applicants: Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University
    Inventors: Jan GRIMM, Monica L. GUZMAN, Charalambos KAITTANIS
  • Publication number: 20180126002
    Abstract: Disclosed are compositions and methods for identifying a solid tumor cell target. Compositions and methods for treating prostate cancer are also disclosed. Further, cancer therapeutic compositions comprising CT20p are disclosed. Nanoparticles that are conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein are disclosed.
    Type: Application
    Filed: April 28, 2016
    Publication date: May 10, 2018
    Inventors: Annette Khaled, Jesus Manuel Perez Figueroa, Santimukul Santra, Charalambos Kaittanis, Oscar Santiesteban, Jan Grimm, Hampton Sessions
  • Publication number: 20180021265
    Abstract: Methods and compositions described herein use polysaccharide nanoparticles (or polysaccharide-coated nanoparticles) to retain and deliver unaltered therapeutic agents to sites of disease. The polysaccharide nanoparticles are non-covalently associated with the unaltered therapeutic agent. The polysaccharide is able to retain cargo (drugs, diagnostics, etc.) without chemical modification of the agent. The nanoparticle maintains its association with the agent through non-covalent interactions but releases its agent in response to changes in the microenvironment, e.g., at the site of cancer cells or cancer tissue.
    Type: Application
    Filed: February 17, 2016
    Publication date: January 25, 2018
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Jan GRIMM, Charalambos KAITTANIS, Travis M. SHAFFER
  • Publication number: 20170252433
    Abstract: The present invention provides methods of treating disease by modulation of PSMA activity. Such modulations can lead to, for example, alterations in cancer tumor metabolism, oxygenation, vascularization, and metastasis. The present invention encompasses the recognition that PSMA, through its role in a complex signaling cascade, can affect cancer progression, angiogenesis, and neovascularization. The present invention provides, among other things, methods of treating cancer, including but not limited to cancer initiation, progression, metastasis, and vascularization by modulation of PSMA activity.
    Type: Application
    Filed: October 9, 2015
    Publication date: September 7, 2017
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Jan Grimm, Charalambos Kaittanis
  • Publication number: 20160074434
    Abstract: Differential surface-charge-dependent localization of nanoceria in normal cells and cancer cells plays a critical role in the toxicity profile of a nanoceria particle. Engineered surface-coated cerium oxide nanoparticles with different surface charges that are positive, negative and neutral provide therapeutic results for normal and cancer cell lines. Results show that nanoceria with a positive or neutral charge enters most of the cell lines studied, while nanoceria with a negative charge internalizes mostly in the cancer cell lines. Moreover, upon entry into the cells, nanoceria is localized to different cell compartments (e.g. cytoplasm and lysosomes) depending on the nanoparticle surface charge. The internalization and subcellular localization of nanoceria plays a key role in the nanoparticle cytotoxicity profile, exhibiting significant toxicity when they localize in the lysosomes of the cancer cell lines.
    Type: Application
    Filed: September 23, 2015
    Publication date: March 17, 2016
    Applicant: University of Central Florida Research Foundation, Inc.
    Inventors: Jesus Manuel Perez, Atul Asati, Santimukul Santra, Charalambos Kaittanis
  • Publication number: 20160074334
    Abstract: Differential surface-charge-dependent localization of nanoceria in normal cells and cancer cells plays a critical role in the toxicity profile of a nanoceria particle. Engineered surface-coated cerium oxide nanoparticles with different surface charges that are positive, negative and neutral provide therapeutic results for normal and cancer cell lines. Results show that nanoceria with a positive or neutral charge enters most of the cell lines studied, while nanoceria with a negative charge internalizes mostly in the cancer cell lines. Moreover, upon entry into the cells, nanoceria is localized to different cell compartments (e.g. cytoplasm and lysosomes) depending on the nanoparticle surface charge. The internalization and subcellular localization of nanoceria plays a key role in the nanoparticle cytotoxicity profile, exhibiting significant toxicity when they localize in the lysosomes of the cancer cell lines.
    Type: Application
    Filed: September 23, 2015
    Publication date: March 17, 2016
    Applicant: University of Central Florida Research Foundation, Inc.
    Inventors: Jesus Manuel Perez, Atul Asati, Santimukul Santra, Charalambos Kaittanis
  • Patent number: 9119391
    Abstract: Methods, systems and compositions are disclosed wherein normal, non-transformed, healthy biological cells are protected from oxidative stress, radiation therapy and chemotherapy while diseased, transformed cells, such as, cancer cells, are provided no protection by the biocompatible, polymer coated nanoceria composition of the present invention. The polymer-coated nanoceria preparation herein exhibits no toxicity to normal cells and exhibits pH-dependent antioxidant properties at neutral or physiological pH values, between approximately 6.5 to approximately 11.0 and is inactive as an antioxidant at acidic pH values between approximately 2.0 to approximately 6.4. Improved therapeutic agents and cytoprotecting devices are based on the newly discovered, pH dependent properties of polymer-coated nanoceria that provide selective cytoprotection.
    Type: Grant
    Filed: July 8, 2008
    Date of Patent: September 1, 2015
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Jesus Manuel Perez, Atul Asati, Sudip Nath, Charalambos Kaittanis
  • Publication number: 20150231269
    Abstract: The present invention relates to the field of drug delivery, in particular the delivery of unmodified cargo molecules (such as doxorubicin and Taxol®) using iron oxide nanoparticles as therapeutic delivery agents. Specifically described are methods to entrap cargo (i.e. known therapeutics (drugs) and other types of molecules) into the exterior coating of iron oxide nanoparticles, including iron oxide nanoparticles approved for use in humans. Additionally, methods describe the use of such drug-loaded nanoparticles as therapeutic delivery agents. Further, methods include quantifying and visualizing the amount of cargo molecule loading levels when preparing these therapeutic agents and then quantifying and visualizing the amount of delivery (i.e. unloading) of these cargo molecules from these nano-particles using compact magnetic relaxometers, common NMR instruments and magnetic resonance imaging (MRI) instruments.
    Type: Application
    Filed: September 19, 2013
    Publication date: August 20, 2015
    Inventors: Charalambos Kaittanis, Jan Grimm
  • Patent number: 9109249
    Abstract: Disclosed herein are methods and materials for facilitating the detection of nucleic acid analytes of interest. Specifically exemplified herein are methods for detecting mycobacterial microorganisms, namely Mycobacterium avium spp. paratuberculosis. Also disclosed is new hybridizing magnetic relaxation nanosensor (hMRS) particularly adapted to detect a target nucleic acid analyte of interest.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: August 18, 2015
    Assignee: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Saleh Naser, J. Manuel Perez, Charalambos Kaittanis
  • Patent number: 9057094
    Abstract: A method of testing bacterial cells for antimicrobial susceptibility includes preparing a suspension of the bacterial cells in a non-nutrient medium, mixing with the suspension an antimicrobial, a carbohydrate usable by the bacterial cells, metallic nanoparticles, and a lectin, and incubating the mixture while monitoring a parameter of the nanoparticles responsive to use of the carbohydrate by the bacterial cells. More broadly stated, the invention includes a method of testing an agent for its effect on cell metabolism by preparing a suspension of cells in a non-nutrient medium, mixing the suspension with the agent, adding a carbohydrate usable by the cells, metallic nanoparticles, and a lectin with binding specificity for the added carbohydrate, and monitoring a nanoparticle parameter responsive to the cells.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: June 16, 2015
    Assignees: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC., NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS
    Inventors: J. Manuel Perez, Charalambos Kaittanis, Sudip Nath
  • Publication number: 20150087605
    Abstract: Disclosed are compositions and methods for treating anthrax, inhibiting anthrax toxins and inhibiting anthrax toxin-induced cytotoxicity. Carboxylic acid-containing small molecules can be used in the methods and compositions disclosed herein, for example, sulindac and derivatives thereof may be used. Methods of screening for carboxylic acid-containing small molecules that can be used to treat anthrax are disclosed. Targeting the anthrax toxin reduces the risks of anthrax spores.
    Type: Application
    Filed: September 19, 2014
    Publication date: March 26, 2015
    Inventors: J. Manuel Perez Figueroa, Oscar Santiesteban, Charalambos Kaittanis
  • Patent number: 8883519
    Abstract: Methods, systems, compositions include biocompatible polymer coated nanoceria that function as aqueous redox catalyst with enhanced activity at an acidic to moderately alkaline pH value between 1 and 8. The compositions are used as oxidizing agents for decomposition, decontamination or inactivation of organic contaminants, such as, pesticides and chemical warfare agents. Another use includes nanoceria as targetable nanocatalyst prepared by conjugating various targeting ligands to the nanoparticle coating to form a colorimetric or fluorescent probe in immunoassays and other molecule binding assays that involve the use of a molecule in solution that changes the color of the solution or emits a fluorescent signal, where localization of nanoceria to organs or tissue is assessed by treatment with an oxidation sensitive dye or other detection devices.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: November 11, 2014
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: J. Manuel Perez, Atul Asati, Santimukul Santra, Charalambos Kaittanis, Sudip Nath
  • Publication number: 20140220565
    Abstract: Disclosed herein are methods and materials for facilitating the detection of nucleic acid analytes of interest. Specifically exemplified herein are methods for detecting mycobacterial microorganisms, namely Mycobacterium avium spp. paratuberculosis. Also disclosed is new hybridizing magnetic relaxation nanosensor (hMRS) particularly adapted to detect a target nucleic acid analyte of interest.
    Type: Application
    Filed: May 21, 2012
    Publication date: August 7, 2014
    Applicant: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Saleh Naser, J. Manuel Perez, Charalambos Kaittanis